Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.38 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.38 |
| ▸ | GALR3 | O60755 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23133545 | 0.87 | ALDH1A1 (0.38) | ALDH1A1CHRM5CHRM1CHRM3TSHR | |
| SCHEMBL17253261 | 0.85 | ALDH1A1 (0.50) | ALDH1A1CHRM5CHRM1CHRM3TSHR | |
| SCHEMBL14712717 | 0.84 | LMNA (0.34) | TSHRLMNA | |
| SCHEMBL423666 | 0.82 | LMNA (0.33) | LMNA | |
| SCHEMBL28708551 | 0.82 | LMNA (0.39) | CHRM5CHRM1CHRM3TSHRCHRM2 | |
| SCHEMBL12608885 | 0.81 | ADRB2 (0.36) | LMNA | |
| SCHEMBL454478 | 0.79 | ALDH1A1 (0.35) | ALDH1A1CHRM5CHRM1CHRM3TSHR | |
| SCHEMBL1892585 | 0.78 | — | — | |
| SCHEMBL1040128 | 0.77 | ALDH1A1 (0.43) | ALDH1A1CHRM5CHRM1CHRM3TSHR | |
| SCHEMBL16327847 | 0.77 | ALDH1A1 (0.48) | ALDH1A1CHRM5CHRM1CHRM3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3566719-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES | Cerulean Pharma Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| US-20170362346-A1 | METHODS AND SYSTEMS FOR POLYMER PRECIPITATION AND GENERATION OF PARTICLES | CERULEAN PHARMA INC (US) | 2017-12-21 | — | — | US | disclosed |
| US-9610360-B2 | Polymer drug conjugates with tether groups for controlled drug delivery | CERULIEAN PHARMA INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9598503-B2 | Methods and systems for polymer precipitation and generation of particles | CERULEAN PHARMA INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160166567-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160101185-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-20160082111-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160058873-A1 | Cyclodextrin-Based Polymers for Therapeutic Delivery | CERULEAN PHARMA INC (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160058875-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20130202659-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130196946-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8497365-B2 | Cyclodextrin-based polymers for therapeutics delivery | INSERT THERAPEUTICS, INC. | 2013-07-30 | — | — | US | disclosed |
| US-20130164282-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130096293-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130029909-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. | 2013-01-31 | — | — | US | disclosed |
| US-20120302505-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120065161-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120058971-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120052097-A1 | THERAPEUTIC PEPTIDE-POLYMER CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | CERULEAN PHARMA INC. (US) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058971-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | ALDH1A1 3011/4885CHRM5 4196/4885CHRM1 4598/4885 |
| US-20130202659-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | ALDH1A1 1992/4885CHRM5 4316/4885CHRM1 4620/4885 |
| US-20160082111-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | ALDH1A1 3011/4885CHRM5 4196/4885CHRM1 4598/4885 |
| US-20160058873-A1 | Cyclodextrin-Based Polymers for Therapeutic Delivery | IAPP, PRCP, DDOST | ALDH1A1 4479/4885CHRM5 3181/4885CHRM1 3691/4885 |
| US-20130096293-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | DDOST, STT3B, STT3A | ALDH1A1 2326/4885CHRM5 4178/4885CHRM1 4551/4885 |
| US-20160101185-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | ALDH1A1 1266/4885CHRM5 4032/4885CHRM1 4197/4885 |
| US-20130196946-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | ALDH1A1 3011/4885CHRM5 4196/4885CHRM1 4598/4885 |
| US-20130029909-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | ALDH1A1 1266/4885CHRM5 4032/4885CHRM1 4197/4885 |
| US-20120052097-A1 | THERAPEUTIC PEPTIDE-POLYMER CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | IAPP, PSAP, LNPEP | ALDH1A1 4482/4885CHRM5 4644/4885CHRM1 4797/4885 |
| US-20120065161-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | DDOST, SDCBP, STT3B | ALDH1A1 2405/4885CHRM5 4130/4885CHRM1 4492/4885 |
| US-20130164282-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | ALDH1A1 1266/4885CHRM5 4032/4885CHRM1 4197/4885 |
| US-20120302505-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | IAPP, PRCP, DDOST | ALDH1A1 4479/4885CHRM5 3181/4885CHRM1 3691/4885 |
| US-20160166567-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | ALDH1A1 1266/4885CHRM5 4032/4885CHRM1 4197/4885 |
| US-20160058875-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | ALDH1A1 1266/4885CHRM5 4032/4885CHRM1 4197/4885 |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | ALDH1A1 2989/4885CHRM5 3146/4885CHRM1 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.